News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Evoke Pharma, Inc. Announces Pricing of Initial Public Offering of 2,100,000 Shares of Common Stock


9/25/2013 8:56:40 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, Sept. 24, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc., a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the pricing of its initial public offering of 2,100,000 shares of its common stock at a public offering price of $12.00 per share. The gross proceeds to Evoke Pharma from the initial public offering are expected to be $25,200,000, before underwriting discounts and commissions and estimated offering expenses. Evoke has granted the representative of the underwriters a 30 day option to purchase up to 315,000 additional shares of common stock from the Company to cover over-allotments, if any. Shares of Evoke's common stock have been approved for listing on the NASDAQ Capital Market under the symbol "EVOK" and are expected to begin trading on September 25, 2013.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES